In advanced SM and myelofibrosis, midostaurin (MIDO) and ruxolitinib (RUX), respectively, must navigate complex mutational landscapes while trying to impact similar disease-related burdens. Professional illustration by Ian Baker; conceived by Jason Gotlib.